Newpace Overview
NewPace develops a flexible and subcutaneous implantable cardioverter defibrillator (ICD) with no leads within the heart with a wireless rechargeable battery and Bluetooth communication. The NewPace defibrillator differs from standard ICDs in that it does not have leads in the heart. The rechargeable device is implanted subcutaneously with no need for fluoroscopy and communicates via Bluetooth with a smartphone. The string-shaped defibrillator requires one hour per year for wireless recharge and communicates at low energy with smartphones for monitoring. The subcutaneous implantation requires no in-patient care. NewPace partners with China-based Haisco Pharmaceutical.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
NewPace Selects Wireless Power Market Leader Powermat Technologies to Develop Advanced Wireless Charging Technology for Innovative Life-Saving Devices
Powermat Technologies announced that NewPace Ltd. will leverage their wireless charging technology for their newest devices in the field of cardiac rhythm management. Powermats wireless chargers for medical devices are now available to support a wide variety of devices, providing safe and easy-to-use power solutions. The integration of wireless charging technology reduces battery size and offers a more comfortable charging experience for patients. Powermat aims to make wireless power a standard feature for medical devices and implantables.
Partners
growth-positive
HRS 2017: New implantable string subcutaneous defibrillator shows promise for sudden cardiac death prevention - Cardiac Rhythm News
A feasibility study on a novel implantable string subcutaneous defibrillator (ISSD) was presented at a medical conference. The ISSD, developed by Newpace, is a less invasive and more aesthetically pleasing alternative to current subcutaneous defibrillators. The study showed that the ISSD successfully defibrillated patients and had a fast implantation time. The device has the potential to improve patient compliance and satisfaction. The researchers hope to further develop the device for chronic implants and multiple sizes. They also anticipate that future versions of the ISSD will be rechargeable.
CustomersExpand
growth-positive
Novel String-Shaped Subcutaneous ICD Proves Effective in Patients
Tenax Therapeutics, Inc. has successfully completed a first-in-man study for the implantation of a string-shaped rechargeable device. The study proves the feasibility of the device, which is a promising emerging treatment for comatose adult cardiac arrest patients. Tenax Therapeutics, Inc. is a medical technology company focused on elevating care for people affected by stroke and cardiovascular diseases. The company has also released a new study on acoustic and AI-based cardiac diagnostics. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2M |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.newpacemedical.com |
| Careers | Careers page |
Locations
Granit Street 13, Caesarea, Israel
Photos & Videos
2 item(s)
